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clonogenicity in vitro via production of inducible TNF-
 upon
contact with HSC. Co-culture of FC with HSC induces pro-
duction of physiologically relevant low levels of TNF-
 by FC.
FC from TNF-
-deleted (TNF-
/) mice are signiﬁcantly
impaired in function in vitro and in facilitating HSC engraft-
ment in vivo in syngeneic recipients as well as allogeneic recip-
ients. A syngeneic model for limiting numbers of HSC (c-Kit/
Sca-1/Lin) was used to evaluate facilitation by TNF-
/
FC. Notably, while 80% of recipients of 500 B6 HSC  30,000
B6 FC engraft durably, none of the recipients of 500 B6 HSC
plus 30,000 TNF-
/ FC engrafted. Furthermore, neutraliza-
tion of TNF-
 on FC using anti-TNF antibody results in loss of
FC effect on HSC clonogenicity in vitro, conﬁrming a direct
and critical role for TNF-
 in FC function. Notably, co-culture
of FC with HSC is associated with signiﬁcant upregulation of
the anti-apoptotic I-B family member Bcl-3 in HSC. Blocking
of TNF-
 on FC abrogates the upregulation of Bcl-3 in HSC.
Taken together, these ﬁndings demonstrate that TNF-
-in-
duced in FC by contact with HSC affects highly primitive HSC
and identify Bcl-3 as a possible pathway for TNF-
 in promot-
ing HSC survival and engraftment efﬁciency.
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SUPERIOR EX VIVO CORD BLOOD TNC AND HEMATOPOIETIC PROGEN-
ITOR CELL EXPANSION FOLLOWING CO-CULTURE WITH BONE MAR-
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Karandish, S.1, Kaur, I.1, Fu, P.1, Del Angel, M.1, Messinger, R.1,
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One factor limiting the therapeutic efﬁcacy of cord blood (CB)
hematopoietic progenitor cell (HPC) transplantation is the low
cell dose of the graft. Low cell dose is associated with an
increased incidence of delayed or failed engraftment. However,
cell dose can be increased and the efﬁcacy of CB transplantation
potentially improved by ex vivo CB expansion prior to trans-
plantation. Two ex vivo CB expansion techniques were com-
pared and hematopoietic output followed by measuring total
nucleated cell (TNC), CD133 and CD34, colony-forming
unit (CFU) and cobblestone area-forming cell (CAFC) num-
bers. Technique 1: Ex vivo culture of CD133-selected cells;
and Technique 2: Co-culture of unmanipulated CB with allo-
geneic bone-marrow-derived mesenchymal stem cell (MSC)
monolayers. In both cases, ex vivo culture was performed in
medium supplemented with granulocyte colony-stimulating fac-
tor (G-CSF), stem cell factor (SCF) and either thrombopoietin
(TPO) or megakaryocyte growth and differentiation factor
(MDGF). When compared to ex vivo liquid culture, ex vivo
CB-MSC co-culture (1) required less cell manipulation result-
ing in less initial HPC loss and (2) markedly improved TNC
(	10-fold), CFU (	25-fold), CD133 (	7-fold) CD34 (	14-
fold), CAFCwk2 (	200-fold), and CAFCwk6 (	44-fold) output.
In addition, MSC have also been shown to promote hematopoi-
etic engraftment in animal models and to possess immunomodu-
latory activities and have been shown to reduce the severity of
graft versus host disease. One concern associated with any ex
vivo expansion strategy is that short-term reconstituting, lower
quality HPC will be expanded at the expense of long-term
reconstituting, higher quality HPC, thereby signiﬁcantly im-
pacting the hematopoietic reserve of the graft. Here we dem-
onstrate that although neither technique signiﬁcantly expanded
the more primitive CAFCwk6 population, they were better pre-
served in the CB-MSC co-culture system. Although the expan-
sion of the more mature components of the hematopoietic
system (TNC, CFU, CD133, CD34, and CAFCwk2) in both
cases was at the expense of the more primitive HPC, in neither
case was the CAFCwk6 compartment completely exhausted,
thereby potentially preserving part of the hematopoietic reserve
of the graft. In improving TNC and HPC expansion, ex vivo
CB-MSC co-culture therefore holds promise for improving
engraftment kinetics and post-transplant complications in CB
transplant recipients.
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IDIOPATHIC SECONDARY POST-TRANSPLANT THROMBOCYTOPENIA
(ISPT) FOLLOWING AUTOLOGOUS HEMATOPOIETIC PROGENITOR
CELL TRANSPLANTATION (HPCT) IS ASSOCIATED WITH TRANSPLAN-
TATION OF LOWER NUMBERS OF PRIMITIVE HEMATOPOIETIC PRO-
GENITORS
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Background: Platelet counts often drop after initial hemato-
poietic engraftment. We hypothesized that secondary thrombo-
cytopenia is related to the stem cell content of the graft. Meth-
ods: We performed a retrospective analysis of 323 consecutive
patients who underwent autologous blood (97%) or BM (3%)
HPCT between 2000 and 2005 for Hodgkin’s lymphoma (n 
53), NHL (n  85), multiple myeloma (n  166), acute leuke-
mia (n  16), and solid tumor (n  5). ISPT was deﬁned as a
	50% decline in blood platelets following initial engraftment to
a value less than 100 K/mcL, in the absence of infection or
relapse, in the ﬁrst 100 days post-transplant. Engraftment,
transfusions, infections, relapse, and survival were recorded with
a median follow-up of 410 days. Results: 303 patients were
evaluable and achieved a transfusion-independent platelet count
of 	20K/mcL, at a median of 17 days post-transplant. The
maximal platelet count was a median of 192 K/mcL and oc-
curred on a median of 22 days. Sixty-three patients (21%) had
secondary thrombocytopenia after initial engraftment, with 3
cases of relapse and 11 cases of sepsis, leaving 49 patients (15%)
with ISPT, and 254 controls. Patients with ISPT engrafted at a
median of 17 days, with a maximal platelet count of 162 K/mcL
on day 19. Platelet counts in ISPT patients dropped to a nadir
of 34 K/mCL (range 4 K–98 K/mcL) on day 35 with subsequent
recovery to a median of 148 K/mcL on day 71. Mean CD34
cells/kg transplanted in ISPT patients (9  7  10E6/kg) were
similar to cell doses transplanted in controls (11  14  10E6/
kg), but IPST patients received fewer CD34CD38 HPC
(0.08  0.08  10E6/kg) versus controls (0.13  0.24  10E6/
kg, P  .005, 2 sided T-test). HIT and anti-platelet antibodies
were absent, and only 16% of BM biopsies in patients with ISPT
had increased megakaryocytes. Fourteen of forty-nine patients
with ISPT received steroids and/or IVIG and had similar plate-
let recoveries to those not treated. Lymphoma patients and
recipients of busulfan conditioning regimens were over-repre-
sented in patients with ISPT compared to controls (P  .001).
Three-year actuarial survival was not signiﬁcantly different be-
tween the 49 ISPT cases (79%) versus the 254 controls (76%).
Conclusions: ISPT occurring within the ﬁrst 100 days after
autologous HPCT is common, and associated with transplanta-
tion of lower numbers of phenotypically primitive HPC. IPST
does not appear to be an auto-immune phenomenon, is self-
limited, and is not associated with adverse long-term survival
(Table1).
Table 1. Comparison of IPST Cases vs Controls
Age
(years)
Gender
(male)
HL and
NHL*
Pre-trx
XRT
Median
day Plt
engrafted
BM
cellularity
day 40–45
Platelet
transfusion
increment
IPST
N  49 48 years 55% 73% 4% 17 days 35% 32K/mcL
Controls
N 
254 51 years 63% 36% 7% 17.5 days 34% 31K/mcL
*P  .001
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